| Autor: |
McDonald MF; Baylor College of Medicine, Houston, United States., Curry RN; Baylor College of Medicine, Houston, TX, United States., O'Reilly I; Baylor College of Medicine, Houston, TX, United States., Lozzi B; Baylor College of Medicine, Houston, TX, United States., Cervantes A; Baylor College of Medicine, United States., Lee ZF; Baylor College of Medicine, Houston, TX, United States., Rosenbaum A; Baylor College of Medicine, Houston, TX, United States., He P; Baylor College of Medicine, Houston, TX, United States., Mohila C; Baylor College of Medicine, Houston, TX, United States., Harmanci AO; The University of Texas Health Science Center at Houston, United States., Serin Harmanci A; Baylor College of Medicine, United States., Deneen B; Baylor College of Medicine, Houston, TX, United States., Rao G; Baylor College of Medicine, Houston, TX, United States. |
| Abstrakt: |
Malignant glioma, the most lethal form of brain cancer, presents with an immunosuppressive microenvironment that obstructs tumor cell clearance and hampers immunotherapeutic interventions. Despite advancements in characterizing cellular and extracellular profiles in cancer, the immunosuppressive mechanisms specific to glioma remain poorly understood. We conducted single-cell RNA sequencing of glioma samples, which revealed a select subset of human and mouse glioma cells that express CD83, a marker associated with mature antigen-presenting cells (APCs). To investigate the impact of tumor cell CD83 expression of glioma outcomes, we employed an immunocompetent mouse model of glioma, bioinformatics analyses of human samples and in vitro assays. Our findings revealed that CD83+ tumor cells contribute to tumor growth suppression and are associated with enhanced cytotoxic T cell profiles and activated CD8+ T cells. Increased proinflammatory cytokines were identified in CD83-overexpressing tumor conditions, which were also correlated with long-term CD8+ antitumor responses. Importantly, tumor-derived CD83 could mediate communication with T cells, altering the immune microenvironment to potentially enhance immune related tumor clearance. Collectively, our data suggest that tumor cell expression of CD83 supports the endogenous anti-tumor T cell constituency in malignant glioma. Future research endeavors may aim to further investigate whether CD83 expression can enhance immunotherapeutic approaches and improve patient outcomes. |
